2nd Quarter - Amendment

BROWN RUDNICK LLP for HOSPIRA, INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

S.1244 - FY14 FDA Appropriations bill relating to sequestered user fees.

LobbyistCovered position, as disclosed
HENRY W MENN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1244 (113th)

Health Issues HCR

P.L. 111-148 - Patient Protection and Affordable Health Care Act provisions relating to biosimilar products. Issues relating to generic drug labeling. HR. 1919- Safeguarding America's Pharmaceuticals Act of 2013 S. 957 & S. 959- The Drug Supply Chain of Security Act

LobbyistCovered position, as disclosed
LISA LAYMAN SPA, Sen Stabenow(05-07)
HENRY W MENN Min SD & Counsel, Cmte on Vet Affairs (04)

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 959 (113th), H.R. 1919 (113th), S. 957 (113th)

Pharmacy PHA

H.R. 486- relating to the compounding of drug products House Discussion Draft amending 503A of FFDCA with respect to pharmacy compounding

LobbyistCovered position, as disclosed
HENRY W MENN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 486 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.